Alpine Immune Sciences Inc
NASDAQ:ALPN
Alpine Immune Sciences Inc
Operating Expenses
Alpine Immune Sciences Inc
Operating Expenses Peer Comparison
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Alpine Immune Sciences Inc
NASDAQ:ALPN
|
Operating Expenses
-$107.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$20.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$12.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-11%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$12.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$4.7B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-14%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$7.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-19%
|
See Also
What is Alpine Immune Sciences Inc's Operating Expenses?
Operating Expenses
-107.9m
USD
Based on the financial report for Mar 31, 2024, Alpine Immune Sciences Inc's Operating Expenses amounts to -107.9m USD.
What is Alpine Immune Sciences Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-19%
Over the last year, the Operating Expenses growth was -17%. The average annual Operating Expenses growth rates for Alpine Immune Sciences Inc have been -34% over the past three years , -19% over the past five years .